Now showing items 1-1 of 1
Oral v. pulse intravenous cyclophosphamide : a retrospective analysis of adverse events in a setting with a high burden of infectious disease
(Health & Medical Publishing Group, 2015)
Background. Cyclophosphamide (CPM) is still considered to be the first-line treatment for many life-threatening autoimmune conditions. It does, however, carry a significant risk of serious adverse events, especially ...